The Analyst Landscape: 7 Takes On AnaptysBio
In the preceding three months, 7 analysts have released ratings for AnaptysBio (NASDAQ:ANAB), presenting a wide array of…
Anaptys Top-Line GEMINI-2 Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis; Patients Who Received A Single Dose Of 750mg IV Imsidolimab, 53% Achieved A GPP Physician Global Assessment Score Of 0/1 (Clear Or Almost Clear S…
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.
Unveiling 4 Analyst Insights On AnaptysBio
In the preceding three months, 4 analysts have released ratings for AnaptysBio (NASDAQ:ANAB), presenting a wide array of…
Anaptys Expands Immune Cell Modulator Pipeline With Exclusive License To BDCA2 Modulator Antibody Portfolio From Centessa Pharmaceuticals; Anaptys Will Pay Centessa A One-Time Upfront Cash Payment Of $7M
Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory
Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today?
AnaptysBio Inc (NASDAQ: ANAB) released topline results from its global Phase 3 GEMINI-1 trial of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares.
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers AnaptysBio (NASDAQ:ANAB) shares moved upwards by 17.9% to $22.7 during Monday’s pre-market session. The market value of…
Anaptys To Provide Overview Of Rosnilimab, A PD-1 Agonist, At Virtual R&D Event On Wednesday, Oct. 25
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology
Anaptys Announces Top-Line Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1 (clear or almost clear) at Week 4 (primary endpoint), compared to 13.3% of patients on placebo (p=0.0131) Demonstrated